Shots:

• The 3-armed P-III (DUO-E) study assesses 1L Imfinzi (durvalumab) + CT (carboplatin & paclitaxel) followed by either Imfinzi monotx. or Imfinzi + Lynparza (olaparib) as maintenance therapy, Imfinzi + CT followed by Imfinzi alone vs CT alone for treating newly diagnosed advanced/recurrent endometrial cancer patients (n=699)
• The post-hoc analysis in the pMMR population showed more than double mDoR of 18.7mos. vs 7.6mos. & reduced risk in PFS2 by 32% with the combination vs control arm (median not attained vs 19.5mos.) as well as improvement in time to 1st & 2nd subsequent treatments
• In the dMMR population across the Imfinzi arm, the ORR was 71.4% with mDoR not attained vs the control arm (40.5%mos. & 10.5mos., respectively)

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca Reports the Results for the Combination of Imfinzi, TACE, and Bevacizumab in P-III Trial for Hepatocellular Carcinoma (HCC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com